AboutEl Kendi Pharmaceutical
Our Vision
To be a leader in the pharmaceutical and healthcare solutions industry and the partner of choicein the META region and emerging pharmaceutical markets.
Our mission
To improve the quality of life of our communities by allowingand facilitating their access to high quality products at affordable prices.
EL KENDI is an Algerian pharmaceutical company with foreign direct investment, ambitious and growing drug production, employing a competent and dedicated team that exceeds 1100 people. Led by young managers whose average age does not exceed forty, EL KENDI is an example that it is possible to succeed in the bet of technology transfer when one trusts Algerian graduates.
El Kendi has granted in Algeria one of the largest industrial investments in the pharmaceutical field, it is the factory located at the level of the industrial zone of Sidi Abdellah (Zeralda) for a total amount of 100 million dollars with the new projects underway, in particular the twin plant whose work is in the final phase.
The manufacture of EL KENDI products is carried out according to international standards, in a facility whose plans are approved by the FDA (Food and Drug Administration).
All the usual forms are manufactured, namely dry forms (tablets, capsules, sachets), liquids, creams and gels. The injectable forms, the project of which is at an advanced stage in terms of design, will be a source of additional pride since it is planned to manufacture, among other things, oncology products and Biosimilar Medicines.
EL KENDI is in the top 3 pharmaceutical companies and the first generic company in Algeria.
The company recently joined the regional pharmaceutical group MS Pharma, which is a platform allowing it rapid access to neighboring markets such as Morocco, Tunisia and French-speaking African countries.
EL KENDI is in the process of consolidating its position in the fields of the central nervous system, cardiology, uro-gynecology, oncology and autoimmune diseases. At the same time, the company is enriching its portfolio with hospital products and drugs derived from biotechnology thanks to the acquisition of licenses for new therapies in these classes.
In order to meet its ambitious objectives, El Kendi does not skimp on the implementation of human and material resources intended to propel this company to the rank of an important player on the Algerian market and a leader in the export of medicines from Algeria.
